10051-CBMS-4 CURCUMIN ANALOG COMPOUND A INHIBITS THE GROWTH OF GLIOBLASTOMA BY INDUCING G2/M PHASE ARREST AND APOPTOSIS AT A LOWER CONCENTRATION THAN CURCUMIN
Ryo Ito, Toshihide Hamabe, Masaya Ono, Sonoka Iwashimizu, Kyoko Inai, Yoichi Sunagawa, Yasufumi Katanasaka, Yoshiki Arakawa, Koji Hasegawa, Tatsuya Morimoto · 2023
Read 10051-CBMS-4 CURCUMIN ANALOG COMPOUND A INHIBITS THE GROWTH OF GLIOBLASTOMA BY INDUCING G2/M PHASE ARREST AND APOPTOSIS AT A LOWER CONCENTRATION THAN CURCUMIN by Ryo Ito, Toshihide Hamabe, Masaya Ono, Sonoka Iwashimizu, Kyoko Inai, Yoichi Sunagawa, Yasufumi Katanasaka, Yoshiki Arakawa, Koji Hasegawa, Tatsuya Morimoto (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710617.txt.
Description
Ryo Ito and co-authors test a curcumin-like compound against glioblastoma, an aggressive brain tumour, in work published in 2023. Standard care combines surgery, drugs, and radiation, yet most patients live less than fifteen months. New agents are badly needed, and curcumin from turmeric has shown anti-tumour effects at high doses.
The team compared the compound, called Compound A, with plain curcumin on two human tumour cell lines. Compound A halted cell growth at about a quarter of the dose curcumin needed. At that dose, it did not harm normal brain support cells grown from rats. Further tests showed the compound pauses the cell cycle at a late stage and triggers cell death. The authors present it as a candidate for further study.
Catalog record
| CREATOR | Ryo Ito, Toshihide Hamabe, Masaya Ono, Sonoka Iwashimizu, Kyoko Inai, Yoichi Sunagawa, Yasufumi Katanasaka, Yoshiki Arakawa, Koji Hasegawa, Tatsuya Morimoto |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |